Literature DB >> 10099125

CD8+ cell-derived anti-human immunodeficiency virus inhibitory factor.

E Barker1.   

Abstract

CD8+ cells in human immunodeficiency virus (HIV)-infected individuals develop the ability to control HIV replication not only by destruction of the infected cells but also by controlling the virus in a noncytotoxic fashion that leaves the infected cell functionally intact. The CD8+ noncytotoxic response is mediated by a novel soluble factor known as CD8+ cell antiviral factor (CAF). CAF suppresses HIV replication in the infected cell at the level of viral transcription by interrupting the ability of Tat or host cellular factors to interact with the HIV long terminal repeats. Unlike some strain-specific anti-HIV cytokines, CAF is active against many different virus isolates, including HIV strains that are nonsyncytium- and syncytium-inducing. Of importance, the ability of CD8+ cells to produce CAF and suppress HIV replication plays a critical role in preventing disease progression following HIV infection.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10099125     DOI: 10.1086/314808

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  3 in total

Review 1.  The role of infant immune responses and genetic factors in preventing HIV-1 acquisition and disease progression.

Authors:  C Farquhar; G John-Stewart
Journal:  Clin Exp Immunol       Date:  2003-12       Impact factor: 4.330

Review 2.  The effects of depression, stressful life events, social support, and coping on the progression of HIV infection.

Authors:  J Leserman
Journal:  Curr Psychiatry Rep       Date:  2000-12       Impact factor: 5.285

3.  Immunoglobulin G (IgG) and IgA, but also nonantibody factors, account for in vitro neutralization of human immunodeficiency virus (HIV) type 1 primary isolates by serum and plasma of HIV-infected patients.

Authors:  R Burrer; D Salmon-Ceron; S Richert; G Pancino; G Spiridon; S Haessig; V Roques; F Barre-Sinoussi; A M Aubertin; C Moog
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.